8-K current report · filed Nov 5, 2026

Oncology Institute, Inc. (TOI) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1TOI overview

Short answer

Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Starling Oncology’s financial results for the three months ended September 30, 2026.

Oncology Institute, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release announces Starling Oncology’s financial results for the three months ended September 30, 2026
  • Exhibit 99.1 contains the company’s financial figures and additional financial information
  • Investors should review the exhibit for revenue, cash position, operating results and liquidity implications

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $169.8M, up 24.3%, led by Specialty Pharmacy revenue $109.3M, up 44%
  • Adjusted EBITDA $3.4M versus $(3.5)M, marking a second consecutive positive quarter despite $15.7M net loss
  • Capitated revenue up 40%, while MLR worsened to 81.0% from 67.8% year over year
  • 2026 guidance narrowed: revenue $650M to $660M, Adjusted EBITDA $4M to $6M, free cash flow $5M to $10M
  • Liquidity $36.9M, with $72.5M long-term debt and $5M drawn on the asset-based revolving facility

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Oncology Institute, Inc. 8-K filings

Get the next TOI 8-K as it lands

Follow TOI for push alerts, or ask the research agent what this filing means.